The Serum Institute of India (SII), has announced a strategic investment in IntegriMedical, acquiring a 20% stake in the company. This collaboration aims to advance the development and deployment of Needle-Free Injection System (N-FIS) technology.
This partnership aligns with SII’s vision of ‘Health for All’ and IntegriMedical’s mission to ‘Transform Healthcare Globally.’ Together, they aim to provide patient comfort, increase compliance, reduce needle-stick injuries, and enhance the efficacy of liquid medications via needle-free dispersion.
IntegriMedical has developed a US-patented Needle-Free Injection System that uses a high-velocity jet stream powered mechanically to administer biologics and drugs effectively. This innovative drug delivery solution aims to alleviate pain during administration, providing needle-phobic patients with a stress-free experience.
Commenting on the strategic investment, Mr. Adar Poonawalla, CEO of Serum Institute of India, shared, “At SII, we are constantly seeking opportunities to invest in technologies that align with our mission to make healthcare accessible and affordable for people worldwide. IntegriMedical’s Needle-Free Injection Systems represent a significant advancement in drug delivery, and we envision a needle-free solution to deliver vaccines. This could potentially revolutionize the way we administer vaccines, making the process more comfortable for patients and healthcare professionals.”
“We are excited to have Serum Institute of India as our strategic partner,” said Sarvesh Mutha, Managing Director of IntegriMedical. “This investment is a testament to the potential of our Needle-Free Injection System technology and its ability to revolutionize drug delivery. SII’s expertise in vaccine manufacturing and global distribution will be invaluable as we work towards making our technology more widely accessible to patients worldwide,” he added.
IntegriMedical’s Needle-Free Injection System, also known as N-FIS, has received regulatory approvals from CDSCO, CE, MDSAP, and is ISO 13485 certified. Additionally, the technology is patented in the United States. Ankur Naik, MD of IntegriMedical, has been instrumental in the development and clinical trials of the N-FIS technology, demonstrating its effectiveness in reducing pain and eliminating needle-phobia in patients.
The collaboration between SII and IntegriMedical leverages the strengths of both companies. SII brings its extensive expertise in vaccine manufacturing and global distribution, while IntegriMedical contributes its innovative drug delivery technology and research capabilities. Together, they aim to expand access to care and improve efficiencies in the global healthcare industry.
N-FIS will soon be available in the Indian private market, offering patients and healthcare providers an alternative to traditional needle-based injections. The technology’s advantages include the elimination of needle-phobia, alleviation of pain during administration, convenience of use, and prevention of needle-stick injuries and cross-contamination. This strategic investment marks a significant step forward in making healthcare more accessible and patient-friendly globally.
